SecurityPGLC / Pershing Gold Corporation (715302204)
CEO and PresidentAlfers Stephen D.
IndustryGold And Silver Mining
Institutional Owners41
Institutional Shares7,086,279 - 21.07%
Common Stock Shares Outstanding33,629,260 shares (as of 2018-03-31)
Institutional Value$ 20,139,000 USD

Institutional Stock Ownership and Shareholders()

Pershing Gold Corporation (NASDAQ:PGLC) has 41 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7,086,279 shares. Largest shareholders include Donald Smith & Co., Inc., Ruffer LLP, Vanguard Group Inc, Cambridge Investment Research Advisors, Inc., Mad River Investors, Geode Capital Management, Llc, Horizon Kinetics LLC, Wells Fargo & Company/mn, Bridgeway Capital Management Inc, and Northern Trust Corp.
Pershing Gold Corporation (NASDAQ:PGLC) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 0 25,058 0 52
2018-05-15 13F-HR PIONEER INVESTMENT MANAGEMENT INC 20,964 27,364 30.53 50 56 12.00
2018-05-14 13F-HR Virtu Financial LLC 76,533 22,747 -70.28 184 47 -74.46
2018-05-15 13F-HR Bank of New York Mellon Corp 10,490 15,965 52.19 25 33 32.00
2017-02-10 13F-HR BlackRock Advisors LLC 5,475 5,475 0.00 25 18 -28.00
2018-05-10 13F-HR Spark Investment Management LLC 46,300 0 -100.00 111 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 2,829 3,384 19.62 7 7 0.00
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 244 0 -100.00 1 0 -100.00
2018-05-09 13F-HR BlackRock Inc. 49,660 43,641 -12.12 119 90 -24.37
2018-05-11 13F-HR Delpha Capital Management, Llc 619 0 -100.00 1 0 -100.00
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 117,782 117,782 0.00 282 241 -14.54
2018-07-19 13F-HR BENJAMIN F. EDWARDS & COMPANY, INC. 27 27 0.00 0 0
2018-05-15 13F-HR Horizon Kinetics LLC 0 69,842 0 143
2018-05-14 13F-HR NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 15,995 33
2018-05-10 13F-HR TORONTO DOMINION BANK 81 0
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 1,000 0 -100.00 2 0 -100.00
2018-05-15 13F-HR WOLVERINE TRADING, LLC Put 0 22,600 0 46
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 49,500 65,200 31.72 119 134 12.61
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 31 0
2018-05-17 13F-HR Atlantic Trust Group, LLC 600 600 0.00 1 1 0.00
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 65,000 65,000 0.00 156 133 -14.74
2018-05-09 13F-HR Cambridge Investment Research Advisors, Inc. 570,778 573,278 0.44 1,370 1,175 -14.23
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 555 555 0.00 1 1 0.00
2018-07-17 13F-HR Baystate Wealth Management LLC 1,666 1,666 0.00 3 3 0.00
2018-05-11 13F-HR SEI INVESTMENTS CO 800 800 0.00 2 2 0.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 15,488 10,875 -29.78 37 22 -40.54
2018-05-15 13F-HR STATE STREET CORP 10,200 21
2018-05-15 13F-HR We Are One Seven, Llc 2,166 2,266 4.62 5 5 0.00
2018-05-09 13F-HR NORTHERN TRUST CORP 54,313 54,313 0.00 131 111 -15.27
2018-04-20 13F-HR Seacrest Wealth Management, Llc 200 200 0.00 0 0
2018-05-10 13F-HR Stratos Wealth Partners, LTD. 420 420 0.00 1 1 0.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 2,236 2,236 0.00 10 7 -30.00
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 14,432 0 -100.00 35 0 -100.00
2018-05-11 13F-HR CITADEL ADVISORS LLC 10,875 22
2018-05-14 13F-HR Ruffer LLP 1,139,604 1,739,604 52.65 2,745 3,430 24.95
2018-04-23 13F-HR MAD RIVER INVESTORS 137,093 136,538 -0.40 329 280 -14.89
2018-05-15 13F-HR Advisor Group, Inc. 555 555 0.00 1 1 0.00
2018-05-03 13F-HR DONALD SMITH & CO., INC. 3,251,930 3,251,930 0.00 7,805 6,666 -14.59
2018-05-10 13F-HR Mainstay Capital Management Llc /adv 135 135 0.00 1 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 60 60 0.00 0 0
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 1,140 2,066 81.23 3 4 33.33
2018-05-15 13F-HR VANGUARD GROUP INC 724,441 716,282 -1.13 1,738 1,468 -15.54
2018-05-14 13F-HR RAYMOND JAMES & ASSOCIATES 42,972 42,222 -1.75 103 87 -15.53
2017-02-10 13F-HR BlackRock Fund Advisors 33,638 43,794 30.19 152 143 -5.92
2018-04-18 13F-HR Sonora Investment Management, LLC 2,777 5,693
2018-05-15 13F-HR UBS Group AG 0 4,371 0 9
2018-05-11 13F-HR Cutler Group LP 100 100 0.00 0 0

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Resource Sector Digest: Sandstorm Gold And The Beauty Of Depletion

2018-06-05 seekingalpha
In case you missed out on previous editions of this newsletter, simply click here, here or here to catch up. (50-1)

Zacks Industry Outlook Highlights: Harmony Gold, NovaGold, Pretium and Pershing Gold

2018-05-31 zacks
Chicago, IL – May 31, 2018 – Today, Zacks Equity Research discusses Health Insurance, including Harmony Gold Mining Company Ltd. (HMY - Free Report) , NovaGold Resources Inc. (NG - Free Report) , Pretium Resources Inc. (PVG - Free Report) and Pershing Gold Corp. (PGLC - Free Report) . (22-2)

Why Betting on the Gold Industry Might Be Risky Now

2018-05-30 zacks
Though the market for gold will remain strong for years to come given the demand for jewelry, bars and coins as well as its safe-haven appeal, it has a number of threats lurking. Below, we have discussed some of the key challenges and what investors in the sector should be wary of in the coming months and years. (31-0)

Gold Mining Stock Outlook - June 2018

2018-05-29 zacks
Per the data available from the World Gold Council, global demand for gold declined 7% year over year to 973.5 tons in the first quarter of 2018 — the weakest first quarter in 10 years. The weak performance can primarily be attributed to a fall in investment demand for gold bars and gold-backed ETFs, partly due to range-bound gold prices. Let’s delve deeper and analyze the factors that led to the decline and also find out what is in store for the yellow metal. (21-0)

Could Rampant Red Flags Drown Aphria's Proposed Nuuvera Acquisition?

2018-03-21 seekingalpha
We see multiple red flags with Aphria’s proposed purchase of Nuuvera, a company that was incorporated in January '17 and had revenue of only ~$30k from inception to September '17. (192-2)

CUSIP: 715302204